Dr. Arshad M. Khanani discussed the 4-year efficacy and safety outcomes of faricimab in treating diabetic macular edema at the ASRS meeting. The RHONE-X extension study showed that patients maintained improvements in vision and central subfield thickness, with over 90% achieving absence of DME by the end of the study. Faricimab was well tolerated through years 3 and 4 of the study. The data suggests that starting or switching to faricimab can be beneficial for controlling the disease and improving DME status. This information is relevant for clinicians and builds on previous trial findings.
Source link
Extension study shows long-term efficacy, safety of faricimab in DME
